Timing of breast cancer surgery during the menstrual cycle‑is there an optimal time of the month? (Review)
- Authors:
- Sarah M. Bernhardt
- Pallave Dasari
- David Walsh
- Amanda R. Townsend
- Timothy J. Price
- Wendy V. Ingman
-
Affiliations: Discipline of Surgery, Adelaide Medical School, The Queen Elizabeth Hospital, University of Adelaide, Woodville, South Australia 5011, Australia, Department of Medical Oncology, The Queen Elizabeth Hospital, Woodville, South Australia 5011, Australia - Published online on: June 24, 2020 https://doi.org/10.3892/ol.2020.11771
- Pages: 2045-2057
-
Copyright: © Bernhardt et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Vogel PM, Georgiade NG, Fetter BF, Vogel FS and McCarty KS Jr: The correlation of histologic changes in the human breast with the menstrual cycle. Am J Pathol. 104:23–34. 1981.PubMed/NCBI | |
|
Ramakrishnan R, Khan SA and Badve S: Morphological changes in breast tissue with menstrual cycle. Mod Pathol. 15:1348–1356. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Brisken C: Progesterone signalling in breast cancer: A neglected hormone coming into the limelight. Nat Rev Cancer. 13:385–396. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ratajczak HV, Sothern RB and Hrushesky WJ: Estrous influence on surgical cure of a mouse breast cancer. J Exp Med. 168:73–83. 1988. View Article : Google Scholar : PubMed/NCBI | |
|
Hrushesky WJ, Bluming AZ, Gruber SA and Sothern RB: Menstrual influence on surgical cure of breast cancer. Lancet. 2:949–952. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Senie RT, Rosen PP, Rhodes P and Lesser ML: Timing of breast cancer excision during the menstrual cycle influences duration of disease-free survival. Ann Intern Med. 115:337–342. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Badwe RA, Gregory WM, Chaudary MA, Richards MA, Bentley AE, Rubens RD and Fentiman IS: Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet. 337:1261–1264. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Veronesi U, Luini A, Mariani L, Del Vecchio M, Alvez D, Andreoli C, Giacobone A, Merson M, Pacetti G, Raselli R, et al: Effect of menstrual phase on surgical treatment of breast cancer. Lancet. 343:1545–1547. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Saad Z, Bramwell V, Duff J, Girotti M, Jory T, Heathcote G, Turnbull I, Garcia B and Stit L: Timing of surgery in relation to the menstrual cycle in premenopausal women with operable breast cancer. Br J Surg. 81:217–220. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Saad Z, Vincent M, Bramwell V, Stitt L, Duff J, Girotti M, Jory T, Heathcote G, Turnbull I and Garcia B: Timing of surgery influences survival in receptor-negative as well as receptor-positive breast cancer. Eur J Cancer. 30A:1348–1352. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
von Minckwitz G, Kaufmann M, Dobberstein S, Grischke EM and Diel IJ: Surgical procedure can explain varying influence of menstrual cycle on prognosis of premenopausal breast cancer patients. Breast. 4:29–32. 1995. View Article : Google Scholar | |
|
Mohr PE, Wang DY, Gregory WM, Richards MA and Fentiman IS: Serum progesterone and prognosis in operable breast cancer. Br J Cancer. 73:1552–1555. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Kucuk AI and Atalay C: The relationship between surgery and phase of the menstrual cycle affects survival in breast cancer. J Breast Cancer. 15:434–440. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Milella M, Nisticò C, Ferraresi V, Vaccaro A, Fabi A, D'Ottavio AM, Botti C, Giannarelli D, Lopez M, Cortesi E, et al: Breast cancer and timing of surgery during menstrual cycle: A 5-year analysis of 248 premenopausal women. Breast Cancer Res Treat. 55:259–266. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Corder AP, Cross M, Julious SA, Mullee MA and Taylor I: The timing of breast cancer surgery within the menstrual cycle. Postgrad Med J. 70:281–284. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Wang Y, Zhou L, Yin K, Yin W and Lu J: Prognostic effect of menstrual cycle on timing of surgery in premenopausal breast cancer patients. Am J Surg. 210:506–511. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wobbes T, Thomas CM, Segers MF, Peer PG, Bruggink ED and Beex LV: The phase of the menstrual cycle has no influence on the disease-free survival of patients with mammary carcinoma. Br J Cancer. 69:599–600. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Badwe RA, Wang DY, Gregory WM, Fentiman IS, Chaudary MA, Smith P, Richards MA and Rubens RD: Serum progesterone at the time of surgery and survival in women with premenopausal operable breast cancer. Eur J Cancer. 30A:445–448. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Holli K, Isola J and Hakama M: Prognostic effect of timing of operation in relation to menstrual phase of breast cancer patient-fact or fallacy. Br J Cancer. 71:124–127. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Grant CS, Ingle JN, Suman VJ, Dumesic DA, Wickerham DL, Gelber RD, Flynn PJ, Weir LM, Intra M, Jones WO, et al: Menstrual cycle and surgical treatment of breast cancer: Findings from the NCCTG N9431 study. J Clin Oncol. 27:3620–3626. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Thorpe H, Brown SR, Sainsbury JR, Perren TJ, Hiley V, Dowsett M, Nejim A and Brown JM: Timing of breast cancer surgery in relation to menstrual cycle phase: no effect on 3-year prognosis: The ITS study. Br J Cancer. 98:39–44. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Pujol P, Daures JP, Brouillet JP, Chang S, Rouanet P, Bringer J, Grenier J and Maudelonde T: A prospective prognostic study of the hormonal milieu at the time of surgery in premenopausal breast carcinoma. Cancer. 91:1854–1861. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Nomura Y, Kataoka A, Tsutsui S, Murakami S and Takenaka Y: Lack of correlation between timing of surgery in relation to the menstrual cycle and prognosis of premenopausal patients with early breast cancer. Eur J Cancer. 35:1326–1330. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Holmberg L, Nordén T, Lindgren A, Wide L, Degerman M and Adami HO: Pre-operative oestradiol levels-relation to survival in breast cancer. Eur J Surg Oncol. 27:152–156. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Ben-Eliyahu S, Page GG, Shakhar G and Taylor AN: Increased susceptibility to metastasis during pro-oestrus/oestrus in rats: Possible role of oestradiol and natural killer cells. Br J Cancer. 74:1900–1907. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Takeda Y, Nonaka Y, Yanagie H, Yoshizaki I and Eriguchi M: Correlation between timing of surgery in relation to the menstrual cycle and prognosis of premenopausal breast cancer patients. Biomed Pharmacother. 55 (Suppl 1):133s–137s. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Vanek VW, Kadivar TF and Bourguet CC: Correlation of menstrual cycle at time of breast cancer surgery to disease-free and overall survival. South Med J. 90:780–788. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Badwe RA, Mittra I and Havaldar R: Timing of surgery during the menstrual cycle and prognosis of breast cancer. J Biosci. 25:113–120. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Lemon HM and Rodriguez-Sierra JF: Timing of breast cancer surgery during the luteal menstrual phase may improve prognosis. Nebr Med J. 81:110–115. 1996.PubMed/NCBI | |
|
Mondini G, Decian F, Sorice G, Friedman D, Spirito C, Costantini M, Sormani MP and Civalleri D: Timing of surgery related to menstrual cycle and prognosis of premenopausal women with breast cancer. Anticancer Res. 17:787–790. 1997.PubMed/NCBI | |
|
Klonoff-Cohen H, An R, Fries T, Le J and Matt GE: Timing of breast cancer surgery, menstrual phase, and prognosis: Systematic review and meta-analysis. Crit Rev Oncol Hematol. 102:1–14. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chaudhry A, Puntis ML, Gikas P and Mokbel K: Does the timing of breast cancer surgery in pre-menopausal women affect clinical outcome? An update. Int Semin Surg Oncol. 3:372006. View Article : Google Scholar : PubMed/NCBI | |
|
Kroman N: Timing of breast cancer surgery in relation to the menstrual cycle-the rise and fall of a hypothesis. Acta Oncol. 47:576–579. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Samuel M, Wai KL, Brennan VK and Yong WS: Timing of breast surgery in premenopausal breast cancer patients. Cochrane Database Syst Rev. CD0037202011.PubMed/NCBI | |
|
Sherman BM and Korenman SG: Hormonal characteristics of the human menstrual cycle throughout reproductive life. J Clin Invest. 55:699–706. 1975. View Article : Google Scholar : PubMed/NCBI | |
|
McGuire WL, Hilsenbeck S and Clark GM: Optimal mastectomy timing. J Natl Cancer Inst. 84:346–348. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
McGuire WL: The optimal timing of mastectomy: Low tide or high tide? Ann Intern Med. 115:401–403. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Badwe R, Hawaldar R, Parmar V, Nadkarni M, Shet T, Desai S, Gupta S, Jalali R, Vanmali V, Dikshit R and Mittra I: Single-injection depot progesterone before surgery and survival in women with operable breast cancer: A randomized controlled trial. J Clin Oncol. 29:2845–2851. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Sanchez AM, Flamini MI, Zullino S, Russo E, Giannini A, Mannella P, Naccarato AG, Genazzani AR and Simoncini T: Regulatory actions of LH and follicle-stimulating hormone on breast cancer cells and mammary tumors in rats. Front Endocrinol (Lausanne). 9:2392018. View Article : Google Scholar : PubMed/NCBI | |
|
Sanchez AM, Flamini MI, Russo E, Casarosa E, Pacini S, Petrini M, Genazzani AR and Simoncini T: LH and FSH promote migration and invasion properties of a breast cancer cell line through regulatory actions on the actin cytoskeleton. Mol Cell Endocrinol. 437:22–234. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Silva EG, Mistry D, Li D, Kuerer HM, Atkinson EN, Lopez AN, Shannon R and Hortobagyi GN: Elevated luteinizing hormone in serum, breast cancer tissue, and normal breast tissue from breast cancer patients. Breast Cancer Res Treat. 76:125–130. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Gnant MF, Seifert M, Jakesz R, Adler A, Mittlboeck M and Sevelda P: Breast cancer and timing of surgery during menstrual cycle. A 5-year analysis of 385 pre-menopausal women. Int J Cancer. 52:707–12. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Schenker JG, Meirow D and Schenker E: Stress and human reproduction. Eur J Obstet Gynecol Reprod Biol. 45:1–8. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Nagma S, Kapoor G, Bharti R, Batra A, Batra A, Aggarwal A and Sablok A: To evaluate the effect of perceived stress on menstrual function. J Clin Diagn Res. 9:QC01–QC03. 2015.PubMed/NCBI | |
|
Atalay C, Kanliöz M and Altinok M: Menstrual cycle and hormone receptor status in breast cancer patients. Neoplasma. 49:2782002.PubMed/NCBI | |
|
Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, et al: Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol. 26:1059–1065. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, et al: Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: Predictive value of centrally reviewed expression of estrogen and progesterone receptors-international breast cancer study group. J Clin Oncol. 26:1404–1410. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Oliver DJ and Ingram DM: Timing of surgery during the menstrual cycle for breast cancer: Possible role of growth factors. Eur J Cancer. 31A:325–328. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Balsari A, Casalini P, Tagliabue E, Greco M, Pilotti S, Agresti R, Giovanazzi R, Alasio L, Rumio C, Cascinelli N, et al: Fluctuation of HER2 expression in breast carcinomas during the menstrual cycle. Am J Pathol. 155:1543–1547. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM, Huntsman D, Olivotto IA, Nielsen TO and Gelmon K: Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol. 26:5697–5704. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Lee HJ, Seo AN, Kim EJ, Jang MH, Kim YJ, Kim JH, Kim SW, Ryu HS, Park IA, Im SA, et al: Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer. Br J Cancer. 112:103–111. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Gompel A, Martin A, Simon P, Schoevaert D, Plu-Bureau G, Hugol D, Audouin J, Leygue E, Truc JB and Poitout P: Epidermal growth factor receptor and c-erbB-2 expression in normal breast tissue during the menstrual cycle. Breast Cancer Res Treat. 38:227–235. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ and Harris AL: Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet. 1:1398–1402. 1987.PubMed/NCBI | |
|
Need EF, Selth LA, Trotta AP, Leach DA, Giorgio L, O'Loughlin MA, Smith E, Gill PG, Ingman WV, Graham JD and Buchanan G: The unique transcriptional response produced by concurrent estrogen and progesterone treatment in breast cancer cells results in upregulation of growth factor pathways and switching from a Luminal A to a Basal-like subtype. BMC Cancer. 15:7912015. View Article : Google Scholar : PubMed/NCBI | |
|
Bernhardt SM, Dasari P, Walsh D, Townsend AR, Price TJ and Ingman WV: Hormonal modulation of breast cancer gene expression: Implications for intrinsic subtyping in premenopausal women. Front Oncol. 6:2412016. View Article : Google Scholar : PubMed/NCBI | |
|
Bernhardt SM, Dasari P, Glynn DJ, Woolford L, Raymond W, Moldenhauer LM, Walsh D, Townsend AR, Price TJ and Ingman WV: Abstract P1-10-12: Menstrual cycling critically affects the Oncotype DX 21-gene signature: implications for predictive biomarker assays in premenopausal women. Cancer Res. 80:P1-10-12. 2020. | |
|
McCulloch P, Choy A and Martin L: Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery. Lancet. 346:1334–1335. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Hu XC and Chow LW: Fine needle aspiration may shed breast cells into peripheral blood as determined by RT-PCR. Oncology. 59:217–222. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Juratli MA, Siegel ER, Nedosekin DA, Sarimollaoglu M, Jamshidi-Parsian A, Cai C, Menyaev YA, Suen JY, Galanzha EI and Zharov VP: In vivo long-term monitoring of circulating tumor cells fluctuation during medical interventions. PLoS One. 10:e01376132015. View Article : Google Scholar : PubMed/NCBI | |
|
Mathenge EG, Dean CA, Clements D, Vaghar-Kashani A, Photopoulos S, Coyle KM, Giacomantonio M, Malueth B, Nunokawa A, Jordan J, et al: Core needle biopsy of breast cancer tumors increases distant metastases in a mouse model. Neoplasia. 16:950–960. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Horowitz M, Neeman E, Sharon E and Ben-Eliyahu S: Exploiting the critical perioperative period to improve long-term cancer outcomes. Nat Rev Clin Oncol. 12:213–226. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Fentiman IS: 12. Timing of surgery for breast cancer. Int J Clin Pract. 56:188–190. 2002.PubMed/NCBI | |
|
Garvin S and Dabrosin C: Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. Cancer Res. 63:8742–8748. 2003.PubMed/NCBI | |
|
Garvin S, Nilsson UW, Huss FR, Kratz G and Dabrosin C: Estradiol increases VEGF in human breast studied by whole-tissue culture. Cell Tissue Res. 325:245–251. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Heer K, Kumar H, Speirs V, Greenman J, Drew PJ, Fox JN, Carleton PJ, Monson JR and Kerin MJ: Vascular endothelial growth factor in premenopausal women-indicator of the best time for breast cancer surgery? Br J Cancer. 78:1203–1207. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Saad Z, Bramwell VH, Wilson SM, O'Malley FP, Jeacock J and Chambers AF: Expression of genes that contribute to proliferative and metastatic ability in breast cancer resected during various menstrual phases. Lancet. 351:1170–1173. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Oesterreich S, Deng W, Jiang S, Cui X, Ivanova M, Schiff R, Kang K, Hadsell DL, Behrens J and Lee AV: Estrogen-mediated down-regulation of E-cadherin in breast cancer cells. Cancer Res. 63:5203–5208. 2003.PubMed/NCBI | |
|
Rochefort H, Augereau P, Briozzo P, Capony F, Cavailles V, Freiss G, Garcia M, Maudelonde T, Morisset M and Vignon F: Structure, function, regulation and clinical significance of the 52K pro-cathepsin D secreted by breast cancer cells. Biochimie. 70:943–949. 1988. View Article : Google Scholar : PubMed/NCBI | |
|
Arruvito L, Sanz M, Banham AH and Fainboim L: Expansion of CD4+ CD25+ and FOXP3+ regulatory T cells during the follicular phase of the menstrual cycle: Implications for human reproduction. J Immunol. 178:2572–2578. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Prieto GA and Rosenstein Y: Oestradiol potentiates the suppressive function of human CD4 CD25 regulatory T cells by promoting their proliferation. Immunology. 118:58–65. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Lee JH, Ulrich B, Cho J, Park J and Kim CH: Progesterone promotes differentiation of human cord blood fetal T cells into T regulatory cells but suppresses their differentiation into Th17 cells. J Immunol. 187:1778–1787. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Chua AC, Hodson LJ, Moldenhauer LM, Robertson SA and Ingman WV: Dual roles for macrophages in ovarian cycle-associated development and remodelling of the mammary gland epithelium. Development. 137:4229–4238. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Hodson LJ, Chua AC, Evdokiou A, Robertson SA and Ingman WV: Macrophage phenotype in the mammary gland fluctuates over the course of the estrous cycle and is regulated by ovarian steroid hormones. Biol Reprod. 89:652013. View Article : Google Scholar : PubMed/NCBI | |
|
Mackay IR, Goodyear MD, Riglar C and Penschow J: Effect on natural killer and antibody-dependent cellular cytotoxicity of adjuvant cytotoxic chemotherapy including melphalan in breast cancer. Cancer Immunol Immunother. 16:98–100. 1983. View Article : Google Scholar : PubMed/NCBI | |
|
Hrushesky WJ, Gruber SA, Sothern RB, Hoffman RA, Lakatua D, Carlson A, Cerra F and Simmons RL: Natural killer cell activity: Age, estrous- and circadian-stage dependence and inverse correlation with metastatic potential. J Natl Cancer Inst. 80:1232–1237. 1988. View Article : Google Scholar : PubMed/NCBI | |
|
Hanna N and Schneider M: Enhancement of tumor metastasis and suppression of natural killer cell activity by beta-estradiol treatment. J Immunol. 130:974–980. 1983.PubMed/NCBI | |
|
Berry J, Green BJ and Matheson DS: Modulation of natural killer cell activity by tamoxifen in stage I post-menopausal breast cancer. Eur J Cancer Clin Oncol. 23:517–520. 1987. View Article : Google Scholar : PubMed/NCBI | |
|
Dasari P, Sharkey DJ, Noordin E, Glynn DJ, Hodson LJ, Chin PY, Evdokiou A, Robertson SA and Ingman WV: Hormonal regulation of the cytokine microenvironment in the mammary gland. J Reprod Immunol. 106:58–66. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Clarke RB, Howell A and Anderson E: Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone. Br J Cancer. 75:251–257. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Dabrosin C: Increase of free insulin-like growth factor-1 in normal human breast in vivo late in the menstrual cycle. Breast Cancer Res Treat. 80:193–198. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Papa V, Hartmann KK, Rosenthal SM, Maddux BA, Siiteri PK and Goldfine ID: Progestins induce down-regulation of insulin-like growth factor-I (IGF-I) receptors in human breast cancer cells: Potential autocrine role of IGF-II. Mol Endocrinol. 5:709–717. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Belkaid Y and Hand TW: Role of the microbiota in immunity and inflammation. Cell. 157:121–141. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Rosean CB, Bostic RR, Ferey JCM, Feng T, Azar FN, Tung KS, Dozmorov MG, Smirnova E, Bos PD and Rutkowski MR: Preexisting commensal dysbiosis is a host-intrinsic regulator of tissue inflammation and tumor cell dissemination in hormone receptor-positive breast cancer. Cancer Res. 79:3662–3675. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Flores R, Shi J, Fuhrman B, Xu X, Veenstra TD, Gail MH, Gajer P, Ravel J and Goedert JJ: Fecal microbial determinants of fecal and systemic estrogens and estrogen metabolites: A cross-sectional study. J Transl Med. 10:2532012. View Article : Google Scholar : PubMed/NCBI | |
|
Fuhrman BJ, Feigelson HS, Flores R, Gail MH, Xu X, Ravel J and Goedert JJ: Associations of the fecal microbiome with urinary estrogens and estrogen metabolites in postmenopausal women. J Clin Endocrinol Metab. 99:4632–4640. 2014. View Article : Google Scholar : PubMed/NCBI |
